Covance announced today that it has relocated and significantly upgraded its clinical pharmacology research unit in Evansville, Indiana.
P R E S S R E L E A S E
FOR IMMEDIATE RELEASE
Contact:
Media Relations
+1 (609) 419-2466
Investor Relations
+1 (609) 452-4807
Covance Opens Top-Tier Research Clinic In Evansville, Indiana
EVANSVILLE, IN - June 16, 2008 - Covance Inc., (NYSE: CVD) the world's largest publicly-traded contract research organization, announced today that it has relocated and significantly upgraded its clinical pharmacology research unit in Evansville, Indiana. The $12.4 million stand-alone, purpose-built facility is a premier clinical research unit for conducting first-in-human studies and other complex trials requiring special attention.
The completion of the 50,000 square-foot Evansville facility caps a two-year clinic investment program which included upgraded facilities for clinical research units in Austin, Texas; Daytona Beach, Florida; and Honolulu, Hawaii.
"Our new clinic is truly a top-tier research facility," says Mary Westrick, Vice President and General Manager of Global Clinical Pharmacology. "In addition to our experienced medical team on-site, we can now provide our clients and patients with the safety of around-the-clock emergency response, including Code Blue, from Deaconess Hospital."
Located on the campus of Deaconess Hospital, the new facility features a USP 797-compliant pharmacy for sterile compounding, a large on-site CLIA laboratory for immediate turnaround of human lab samples, and a hospital-like audible emergency call system for patient safety. The Evansville clinic has a database of approximate 41,000 volunteers for participation in Phase I trials.
"We are very excited to introduce our staff and volunteers to the new facility," says Launa Mitchell, Site Director. "Our volunteers will particularly notice the increased levels of comfort and amenities, including an outdoor terrace, two large lounges, wireless Internet and larger patient rooms with TV/VCR/DVD combos."
Covance offers early stage testing at ten clinical sites in the United States and United Kingdom. To learn more about clinical research services at Covance, please call 888-COVANCE (888-268-2623) in the Americas; 44(0)4235-00888 in Europe; or 1-65-65677333 in Asia or visit our website at www.covance.com.
About Covance
Covance, with headquarters in Princeton, New Jersey , is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.5 billion, global operations in more than 20 countries, and more than 8,900 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com .
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.